NKTR Key Statistics, Chart & Performance
The current stock price of NKTR is 58.78 USD. In the past month the price increased by 1.4%. In the past year, price increased by 287.99%.
NKTR Latest News, Press Relases and Analysis
NKTR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.67 | 928.57B | ||
| JNJ | JOHNSON & JOHNSON | 19.26 | 481.76B | ||
| MRK | MERCK & CO. INC. | 11 | 240.48B | ||
| PFE | PFIZER INC | 7.92 | 144.02B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.72 | 103.11B | ||
| ZTS | ZOETIS INC | 18.26 | 51.01B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.27 | 21.99B | ||
| VTRS | VIATRIS INC | 4.8 | 12.89B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.28 | 10.15B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.49 | 8.75B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.32B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.20B |
Related stock screener links
About NKTR
Company Profile
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 61 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Company Info
NEKTAR THERAPEUTICS
455 Mission Bay Boulevard South
San Francisco CALIFORNIA 94158 US
CEO: Howard W. Robin
Employees: 61
Phone: 18554826587
NEKTAR THERAPEUTICS / NKTR FAQ
What does NKTR do?
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 61 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Can you provide the latest stock price for NEKTAR THERAPEUTICS?
The current stock price of NKTR is 58.78 USD. The price increased by 2.62% in the last trading session.
Does NKTR stock pay dividends?
NKTR does not pay a dividend.
How is the ChartMill rating for NEKTAR THERAPEUTICS?
NKTR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of NEKTAR THERAPEUTICS (NKTR)?
NEKTAR THERAPEUTICS (NKTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.82).
Is NEKTAR THERAPEUTICS (NKTR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NKTR.
Can you provide the growth outlook for NEKTAR THERAPEUTICS?
The Revenue of NEKTAR THERAPEUTICS (NKTR) is expected to decline by -56.1% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
NKTR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NKTR. When comparing the yearly performance of all stocks, NKTR is one of the better performing stocks in the market, outperforming 98.46% of all stocks.
NKTR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTR. No worries on liquidiy or solvency for NKTR as it has an excellent financial health rating, but there are worries on the profitability.
NKTR Financial Highlights
Over the last trailing twelve months NKTR reported a non-GAAP Earnings per Share(EPS) of -10.82. The EPS increased by 14.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.07% | ||
| ROE | -141.9% | ||
| Debt/Equity | 0 |
NKTR Forecast & Estimates
14 analysts have analysed NKTR and the average price target is 109.43 USD. This implies a price increase of 86.17% is expected in the next year compared to the current price of 58.78.
For the next year, analysts expect an EPS growth of 9.35% and a revenue growth -56.1% for NKTR